Skip to search formSkip to main contentSkip to account menu

Antihemophilic Factor, Human Recombinant 1 UNT Injection [Kovaltry]

Known as: Kovaltry 1 UNT Injection, ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT 3000 [iU] in 5 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Kovaltry], ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT 2000 [iU] in 5 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Kovaltry] 
National Institutes of Health

Related topics

Related topics

9 relations
Antihemophilic Factor, Human RecombinantCalcium ChlorideGlycineHistidine

Broader (1)

Antihemophilic Factor, Human Recombinant 1 UNT Injection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Bay 81-8973 in the Real World: Clinical Effectiveness and Safety in Patients with Hemophilia Α across the US and Europe
Background: BAY 81-8973 (Kovaltry®, Bayer) is an unmodified full-length recombinant FVIII launched in 2016 in Europe and the US… 
2017
2017
[Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials]
Farmeconomia. Health economics and therapeutic pathways 2017; 18(1) © SEEd All rights reserved Dal punto di vista economico, il… 
2016
2016
[Kovaltry® for the replacement therapy in patients with Hemophilia A]
vazioni della World Federation of Hemophilia riportando una prevalenza della malattia di 6,2/100.000 abitanti; nel 2013, dei 3… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)